European Commission Approves Takeda’s Adcetris for Large-Cell Lymphoma

The European Commission has approved Takeda’s Adcetris (brentuximab vedotin) as an adjunct treatment for adult patients with previously untreated systemic anaplastic large-cell lymphoma (sALCL).

The approval was based on the results of a phase 3 trial in which Adcetris plus cyclophosphamide, doxorubicin and prednisone demonstrated significant improvement in progression-free survival.

Adcetris is approved in the U.S. for several indications, including sALCL.